-+ 0.00%
-+ 0.00%
-+ 0.00%

Hua Medicine swings to RMB 30.2 million H1 FY26 loss; revenue rises 74% to RMB 378.9 million

PUBT·08/20/2026 12:12:59
Listen to the news
Hua Medicine swings to RMB 30.2 million H1 FY26 loss; revenue rises 74% to RMB 378.9 million
  • Hua Medicine posted a loss before tax of RMB 30.2 million, swinging from a profit of RMB 1.18 billion a year earlier.
  • Revenue climbed 74% to RMB 378.9 million, driven by sales of 3,055,000 packs of HuaTangNing, up 73%.
  • Gross profit nearly doubled to RMB 234.3 million; gross margin widened 7.6 percentage points to 61.8% on higher scale and efficiency.
  • Other income fell 99% to RMB 6.5 million after a RMB 1.24 billion contract-liability release tied to the Bayer termination last year.
  • Cash stood at RMB 1.07 billion; Hua Medicine reiterated an aim to reach profitability in 2027 as HuaTangNing scales up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hua Medicine published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12292984), on August 20, 2026, and is solely responsible for the information contained therein.